FDA Botched Amarin's Vascepa Exclusivity, Judge Rules
A D.C. federal judge on Thursday vacated the U.S. Food and Drug Administration's decision to limit market exclusivity for Amarin Pharmaceuticals Ireland Ltd.'s fish oil drug Vascepa, finding that the agency...To view the full article, register now.
Already a subscriber? Click here to view full article